Jazz Pharmaceuticals
Market Cap
US$8.4b
Last Updated
2020/01/24 00:33 UTC
Data Sources
Company Financials +
Executive Summary
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Very undervalued with adequate balance sheet.
Similar Companies
Share Price & News
How has Jazz Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JAZZ has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.3%
JAZZ
-0.5%
US Pharmaceuticals
-0.09%
US Market
1 Year Return
17.5%
JAZZ
15.2%
US Pharmaceuticals
23.9%
US Market
Return vs Industry: JAZZ exceeded the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: JAZZ underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| JAZZ | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -0.5% | -0.09% |
| 30 Day | -3.0% | 2.3% | 3.1% |
| 90 Day | 20.4% | 15.0% | 10.4% |
| 1 Year | 17.5%17.5% | 18.1%15.2% | 26.6%23.9% |
| 3 Year | 24.8%24.8% | 42.8%32.6% | 50.9%41.2% |
| 5 Year | -12.0%-12.0% | 30.6%16.8% | 78.1%58.5% |
Price Volatility Vs. Market
How volatile is Jazz Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
If You Like EPS Growth Then Check Out Jazz Pharmaceuticals (NASDAQ:JAZZ) Before It's Too Late2 weeks ago | Simply Wall St
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Rather Sparingly4 weeks ago | Simply Wall St
Jazz Pharmaceuticals's (NASDAQ:JAZZ) Earnings Are Growing But Is There More To The Story?Valuation
Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JAZZ ($150.23) is trading below our estimate of fair value ($307.91)
Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JAZZ is good value based on its PE Ratio (14.2x) compared to the Pharmaceuticals industry average (24.9x).
PE vs Market: JAZZ is good value based on its PE Ratio (14.2x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: JAZZ is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: JAZZ is good value based on its PB Ratio (2.8x) compared to the US Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
15.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAZZ's forecast earnings growth (15.8% per year) is above the savings rate (1.7%).
Earnings vs Market: JAZZ's earnings (15.8% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: JAZZ's earnings are forecast to grow, but not significantly.
Revenue vs Market: JAZZ's revenue (2.9% per year) is forecast to grow slower than the US market (7.5% per year).
High Growth Revenue: JAZZ's revenue (2.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (22.3%)
Next Steps
Past Performance
How has Jazz Pharmaceuticals performed over the past 5 years?
23.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAZZ has a large one-off loss of $168.2M impacting its September 30 2019 financial results.
Growing Profit Margin: JAZZ's current net profit margins (29.6%) are higher than last year (28.1%).
Past Earnings Growth Analysis
Earnings Trend: JAZZ's earnings have grown significantly by 23.4% per year over the past 5 years.
Accelerating Growth: JAZZ's earnings growth over the past year (17.1%) is below its 5-year average (23.4% per year).
Earnings vs Industry: JAZZ earnings growth over the past year (17.1%) underperformed the Pharmaceuticals industry 36.8%.
Return on Equity
High ROE: JAZZ's Return on Equity (19.9%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Jazz Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($1.5B) exceed its short term liabilities ($390.4M).
Long Term Liabilities: JAZZ's short term assets ($1.5B) do not cover its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: JAZZ's debt to equity ratio (52.6%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has reduced from 100% to 52.6% over the past 5 years.
Debt Coverage: JAZZ's debt is well covered by operating cash flow (56.4%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (11.5x coverage).
Balance Sheet
Inventory Level: JAZZ has a low level of unsold assets or inventory.
Debt Coverage by Assets: JAZZ's debt is not covered by short term assets (assets are 0.9x debt).
Next Steps
Dividend
What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Jazz Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
1.6yrs
Average management tenure
CEO
Bruce Cozadd (55yo)
10.8yrs
Tenure
US$11,443,133
Compensation
Mr. Bruce C. Cozadd co-founded Jazz Pharmaceuticals Public Limited Company (also known as Jazzpharmaceuticals, Inc.) in 2003 and has been Chairman and Chief Executive Officer since April 2009. Mr. Cozadd s ...
CEO Compensation Analysis
Compensation vs Market: Bruce's total compensation ($USD11.44M) is above average for companies of similar size in the US market ($USD6.46M).
Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.6yrs
Average Tenure
56yo
Average Age
Experienced Management: JAZZ's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Age and Tenure
7.8yrs
Average Tenure
58.5yo
Average Age
Experienced Board: JAZZ's board of directors are considered experienced (7.8 years average tenure).
Insider Trading
Insider Buying: JAZZ insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 82 |
| Max Price | US$149.84 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 6,750 |
| Max Price | US$147.82 |
| Entity | Individual |
| Shares | 4,371 |
| Max Price | US$137.40 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Lead Director Lead Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Shares | 817 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 787 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 787 |
| Max Price | US$135.65 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 726 |
| Max Price | US$135.65 |
| Entity | Individual |
| Shares | 1,060 |
| Max Price | US$135.41 |
| Entity | Individual |
| Shares | 874 |
| Max Price | US$139.50 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Bruce Cozadd (55yo)
Co-Founder
- Tenure: 10.8yrs
- Compensation: US$11.44m
Karen Wilson (56yo)
Senior VP of Finance & Principal Accounting Officer
- Tenure: 8yrs
- Compensation: US$1.24m
Dan Swisher (56yo)
President & COO
- Tenure: 2yrs
- Compensation: US$5.75m
Mike Miller (62yo)
Executive Vice President of US Commercial
- Tenure: 5.8yrs
- Compensation: US$2.86m
Jed Black
Senior Vice President of Sleep & CNS Medicine
Matt Young (50yo)
Consultant
- Tenure: 0.3yrs
- Compensation: US$3.36m
Kathee Littrell
Vice President of Investor Relations
Neena Patil
Senior VP & General Counsel
- Tenure: 0.5yrs
Heidi Manna
Senior VP & Chief Human Resources Officer
- Tenure: 1.2yrs
Finbar Larkin
Senior Vice President of Technical Operations
- Tenure: 0.3yrs
Board Members
Ken O’Keefe (52yo)
Independent Director
- Tenure: 16yrs
- Compensation: US$546.92k
Bruce Cozadd (55yo)
Co-Founder
- Tenure: 10.8yrs
- Compensation: US$11.44m
Seamus Mulligan (59yo)
Independent Director
- Tenure: 8yrs
- Compensation: US$554.42k
Peter Gray (64yo)
Independent Director
- Tenure: 6.7yrs
- Compensation: US$569.42k
Norbert Riedel (61yo)
Independent Director
- Tenure: 6.7yrs
- Compensation: US$566.92k
Patrick Enright (58yo)
Independent Director
- Tenure: 10.5yrs
- Compensation: US$559.42k
Paul Berns (52yo)
Independent Director
- Tenure: 10yrs
- Compensation: US$544.42k
Rick Winningham (59yo)
Lead Independent Director
- Tenure: 5.7yrs
- Compensation: US$591.92k
Cathy Sohn (66yo)
Independent Director
- Tenure: 7.5yrs
- Compensation: US$554.42k
Heather McSharry (57yo)
Independent Director
- Tenure: 6.7yrs
- Compensation: US$579.42k
Company Information
Jazz Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Jazz Pharmaceuticals plc
- Ticker: JAZZ
- Exchange: NasdaqGS
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.435b
- Shares outstanding: 56.57m
- Website: https://www.jazzpharma.com
Number of Employees
Location
- Jazz Pharmaceuticals plc
- Waterloo Exchange
- Fifth Floor
- Dublin
- Co. Dublin
- 4
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| JAZZ | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2007 |
| J7Z | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2007 |
Biography
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson’s disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/24 00:33 |
| End of Day Share Price | 2020/01/23 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.